

118TH CONGRESS
1ST SESSION

H. R. 4007

To ensure references to opioid overdose reversal agents in grant programs of the Department of Health and Human Services are not limited to naloxone.

IN THE HOUSE OF REPRESENTATIVES

JUNE 12, 2023

Mr. ARMSTRONG (for himself and Mr. TONKO) introduced the following bill;
which was referred to the Committee on Energy and Commerce

A BILL

To ensure references to opioid overdose reversal agents in grant programs of the Department of Health and Human Services are not limited to naloxone.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Halting the Epidemic
5 of Addiction and Loss Act of 2023” or the “HEAL Act
6 of 2023”.

7 **SEC. 2. REFERENCES TO OPIOID OVERDOSE REVERSAL**
8 **AGENTS IN HHS GRANT PROGRAMS.**

9 (a) IN GENERAL.—The Secretary of Health and
10 Human Services shall ensure that, whenever the Depart-

1 ment of Health and Human Services issues a regulation,
2 guidance, or other document for any grant program ad-
3 dressing opioid misuse and use disorders, any reference
4 to an opioid overdose reversal agent (such as a reference
5 to naloxone) is inclusive of any opioid overdose reversal
6 agent that has been approved or otherwise authorized for
7 use by the Food and Drug Administration.

8 (b) EXISTING REFERENCES.—

9 (1) UPDATE.—Not later than the end of cal-
10 endar year 2023, the Secretary of Health and
11 Human Services shall update all references described
12 in paragraph (2) to be inclusive of any opioid over-
13 dose reversal agent that has been approved or other-
14 wise authorized for use by the Food and Drug Ad-
15 ministration.

16 (2) REFERENCES.—A reference described in
17 this paragraph is any reference to an opioid overdose
18 reversal agent (such as naloxone) in any regulation,
19 guidance, or other document of the Department of
20 Health and Human Services that—

21 (A) was issued before the date of enact-
22 ment of this Act; and

23 (B) is for—

24 (i) the grant program for State and
25 Tribal response to opioid use disorders

1 under section 1003 of the 21st Century
2 Cures Act (42 U.S.C. 290ee–3 note; com-
3 monly referred to as “State Opioid Re-
4 sponse Grants” and “Tribal Opioid Re-
5 sponse Grants”); or

6 (ii) the grant program for priority
7 substance use disorder prevention needs of
8 regional and national significance under
9 section 516 of the Public Health Service
10 Act (42 U.S.C. 290bb–22).

○